Romosozumab effect on neutrophil-to-lymphocyte ratio in post-menopausal women at high risk of fracture
Authors' conclusion
In post-menopausal women with severe osteoporosis, 12 months of ROMO treatment was associated with a statistically significant reduction in NLR, reflecting a potential modulation of systemic inflammation, though the clinical relevance of this modest shift remains uncertain and warrants further investigation.
Study context
- Population
- Post-menopausal women with severe osteoporosis treated with romosozumab (ROMO), October 2023 to April 2025mean age 73.4±9.7 years
- Participants
- 113 women
- Outcome
- Absolute changes in complete blood count (CBC) parameters
- Follow-up
- 12 months
Methodological detailssingle-group, mixed model for repeated measures
- Single-group
- Mixed model for repeated measures
Main finding
As reported in the abstract
NLR over 12 months of ROMO
Baseline
2.0
± 1.1
Month 6
1.8
± 1.1
Month 12
1.8
± 1.2
- Effect size (Cohen's δ), small
- 0.22
Observational data: associations, not effects.
Further findings
Neutrophils · 6 and 12 months
- Significant decrease at 6 months
- P = 0.022
- Not sustained at 12 months
- P = 0.500
Haemoglobin and lymphocytes · 12 months
- No significant differences over the period of the study
Original publication
Romosozumab effect on neutrophil-to-lymphocyte ratio in post-menopausal women at high risk of fracture. Clin Exp Rheumatol. Published 18 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →